Maria Wysocka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Wysocka has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Alain H. Rook
University of Pennsylvania School of Medicine 2 philadelphia, pa
2 shared publications Aasha Gupta
Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA
1 shared publication- Adam Eugene Snook
Thomas Jefferson University
1 shared publication - Adarsh Ravishankar
Department of Dermatology, University of Minnesota, Minneapolis, Minnesota, USA
1 shared publication Aditya Nimmagadda
ViTToria Biotherapeutics, Philadelphia, PA, USA
1 shared publication- Alberto Carturan
University of Pennsylvania, Philadelphia, Pennsylvania, USA
1 shared publication
Latest Publications
- 19 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (97) , eadn6509
CD5 deletion enhances the antitumor activity of adoptive T cell therapies
Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have very poor prognoses. One of the main barriers to the clinical success of adoptive T cell immunotherapies is CAR T cell dysfunction and lack of expansion and/or persistence after infusion. In this study, we found that CD5 inhibits CAR T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR T cells in multiple hematological and solid cancer models. Mechanistically, CD5 KO drives increased T cell effector function with enhanced cytotoxicity, in vivo expansion, and persistence, without apparent toxicity in preclinical models. These findings indicate that CD5 is a critical inhibitor of T cell function and a potential clinical target for enhancing T cell therapies.
- 19 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (97) , eadn6509
CD5 deletion enhances the antitumor activity of adoptive T cell therapies
Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have very poor prognoses. One of the main barriers to the clinical success of adoptive T cell immunotherapies is CAR T cell dysfunction and lack of expansion and/or persistence after infusion. In this study, we found that CD5 inhibits CAR T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR T cells in multiple hematological and solid cancer models. Mechanistically, CD5 KO drives increased T cell effector function with enhanced cytotoxicity, in vivo expansion, and persistence, without apparent toxicity in preclinical models. These findings indicate that CD5 is a critical inhibitor of T cell function and a potential clinical target for enhancing T cell therapies.
- 9 June 2022
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (11) , 1-4
TCF1 and Tox define different subsets of CD4 T cells in patients with Sézary syndrome
Sézary syndrome (SS), a leukemic form of cutaneous T cell lymphoma (CTCL), is a rare T-cell malignancy which is defined by circulating malignant CD4+CD26− T cells [1]. It is characterized by severe...
- 9 June 2022
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (11) , 1-4
TCF1 and Tox define different subsets of CD4 T cells in patients with Sézary syndrome
Sézary syndrome (SS), a leukemic form of cutaneous T cell lymphoma (CTCL), is a rare T-cell malignancy which is defined by circulating malignant CD4+CD26− T cells [1]. It is characterized by severe...
- Open Access
- 4 January 2022
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 24 (1) , 1-11
Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM
Background: Lenabasum is a cannabinoid type 2 receptor (CB2R) reverse agonist that demonstrates anti-inflammatory effects in vivo and in vitro in dermatomyositis (DM) and is currently being investigated for therapeutic potential. The purpose of our study is to investigate CB2R distribution as well as the effects of lenabasum in DM. Methods: Immunohistochemistry staining (IHC) was utilized to examine immune cell and cytokine production changes in lesional DM skin biopsies from lenabasum and placebo-treated patients. CB2R expression in various immune cell populations within DM skin was investigated with image mass cytometry (IMC), whereas flow cytometry elucidated CB2R expression in DM peripheral blood mononuclear cells (PBMCs) as well as cytokine production by CB2R-expressing cell populations. Results: After 12 weeks of lenabasum treatment, IHC staining showed that CD4+ T cells, CB2R, IL-31, IFN-γ, and IFN-β cytokines were downregulated. IFN-γ and IFN-β mRNA decreased in lesional DM skin but not in PBMCs. IMC findings revealed that CB2R was upregulated in DM lesional skin compared to HC skin and DM PBMCs (pp<0.05). These CB2R+ cells in the skin produce IL-31, IL-4, IFN-γ, and IFN-β. Conclusion: Our findings of differential CB2R expression based on location and cell type suggest modes by which lenabasum may exert anti-inflammatory effects in DM and highlights dendritic cells as potential therapeutic targets.
- 4 January 2022
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 24 (1) , 1-11
Open AccessCannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM
Background: Lenabasum is a cannabinoid type 2 receptor (CB2R) reverse agonist that demonstrates anti-inflammatory effects in vivo and in vitro in dermatomyositis (DM) and is currently being investigated for therapeutic potential. The purpose of our study is to investigate CB2R distribution as well as the effects of lenabasum in DM. Methods: Immunohistochemistry staining (IHC) was utilized to examine immune cell and cytokine production changes in lesional DM skin biopsies from lenabasum and placebo-treated patients. CB2R expression in various immune cell populations within DM skin was investigated with image mass cytometry (IMC), whereas flow cytometry elucidated CB2R expression in DM peripheral blood mononuclear cells (PBMCs) as well as cytokine production by CB2R-expressing cell populations. Results: After 12 weeks of lenabasum treatment, IHC staining showed that CD4+ T cells, CB2R, IL-31, IFN-γ, and IFN-β cytokines were downregulated. IFN-γ and IFN-β mRNA decreased in lesional DM skin but not in PBMCs. IMC findings revealed that CB2R was upregulated in DM lesional skin compared to HC skin and DM PBMCs (pp<0.05). These CB2R+ cells in the skin produce IL-31, IL-4, IFN-γ, and IFN-β. Conclusion: Our findings of differential CB2R expression based on location and cell type suggest modes by which lenabasum may exert anti-inflammatory effects in DM and highlights dendritic cells as potential therapeutic targets.